

Percolating HIV Px Pipeline

Strategy	Trial	#	Population	Status	Location
Oral PrEP: Daily oral F/TAF	Discover	5,400	MSM & transgender	Fully enrolled	Austria, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, UK, US
bNAb: VRC01 infused every 2 months	HVTN 704/HPTN 085	2,700	MSM & transgender	Enrolling	Brazil, Peru, Switzerland, US
	HVTN 703/HPTN 081	1,500	Sexually active women	Enrolling	Botswana, Kenya, Malawi, Mozambique, Tanzania, South Africa, Zimbabwe
Vax: ALVAC/gp120 MF59 adjuvant boost, 5 doses in 12 months	HVTN 702	5,400	Sexually active women & men	Enrolling	South Africa
Long-acting injectable: cabotegravir every two months	HPTN 083	4,500	MSM & transgender	Enrolling	Argentina, Brazil, Peru, South Africa, Thailand, US, Vietnam
	HPTN 084	3,200	Sexually active women	Enrolling	Botswana, Kenya, Malawi, South Africa, Swaziland, Uganda, Zimbabwe
HC/HIV: evaluating 3 contraceptives for possible increased risk	ECHO	7,800	Sexually active women	Fully enrolled	Kenya, South Africa, Swaziland, Zambia
Vax: Ad26/Mosaic + gp140 boost, 4 doses in 12 months	HPX2008/HVTN705	2,600	Sexually active women	Enrolling	Malawi, Mozambique, South Africa, Zambia, Zimbabwe
Ring/PrEP: dapivirine ring and oral TDF/FTC	MTN 034/IPM 045/REACH	300	Sexually active women	Planned 2018	Kenya, South Africa, Uganda, Zimbabwe

Percolating Pipeline in PrEP Era

Strategy	Trial	#	Population	Status	Location	PrEP Status
Oral PrEP: Daily oral F/TAF	Discover	5,400	MSM & transgender	Fully enrolled	Austria, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, UK, US	Oral TDF/FTC as part of active control in double-dummy, double-blind design
bNAb: VRC01 infused every 2 months	HVTN 704/HPTN 085	2,700	MSM & transgender	Enrolling	Brazil, Peru, Switzerland, US	Access to oral FTC/TDF PrEP offered at no drug cost to every participant
	HVTN 703/HPTN 081	1,500	Sexually active women	Enrolling	Botswana, Kenya, Malawi, Mozambique, Tanzania, South Africa, Zimbabwe	Oral TDF/FTC discussed in IC, risk reduction counseling sessions, and referral systems
Vax: ALVAC/gp120 MF59 adjuvant boost, 5 doses in 12 months	HVTN 702	5,400	Sexually active women & men	Enrolling	South Africa	
Long-acting injectable: cabotegravir every two months	HPTN 083	4,500	MSM & transgender	Enrolling	Argentina, Brazil, Peru, South Africa, Thailand, US, Vietnam	Oral TDF/FTC as part of active control in double-dummy, double-blind design
	HPTN 084	3,200	Sexually active women	Enrolling	Botswana, Kenya, Malawi, South Africa, Swaziland, Uganda, Zimbabwe	
HC/HIV: evaluating 3 contraceptives for possible increased risk	ECHO	7,800	Sexually active women	Fully enrolled	Kenya, South Africa, Swaziland, Zambia	Participants interested in oral TDF/FTC referred as programs become available in each study community
Vax: Ad26/Mosaic + gp140 boost, 4 doses in 12 months	HPX2008/HVTN705	2,600	Sexually active women	Enrolling	Malawi, Mozambique, South Africa, Zambia, Zimbabwe	TBD
Ring/PrEP: dapivirine ring and oral TDF/FTC	MTN 034/IPM 045/REACH	300	Sexually active women	Planned 2018	Kenya, South Africa, Uganda, Zimbabwe	Open-label cross-over; all will try both ring and oral, then choose